Rction.

BMC Cardiovasc Disord 2010, 10:59. 8. Nomenclature and criteria for diagnosis of ischemic
Rction. BMC Cardiovasc Disord 2010, 10:59. 8. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/ World Health Organization task force on standardization of clinical nomenclature. Circulation 1979, 59:607-609. 9. Myocardial 3-Fluoro-2-(trifluoromethyl)aniline infarction redefined consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21:1502-1513. 10. Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538. 11. Andrikopoulos GK, Richter DJ, Dilaveris PE, Pipilis A, Zaharoulis A, Gialafos JE, Toutouzas PK, Chimonas ET: In-hospital mortality of habitual cigaretteAbbreviations ACE-I: angiotensin converting enzyme inhibitor; ACS: acute coronary syndrome; AMI: acute myocardial infarction; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CCU: coronary care unit; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; ER: emergency room; GRACE: global registry of acute coronary events; HR: hazard ratio; ICU: 5-Triazine-2 intensive care unit; LAD: left anterior descending artery;Aune et al. BMC Medicine 2011, 9:97 http://www.biomedcentral.com/1741-7015/9/Page 11 of12.13.14.15.16.17.18.19.20.21.22.23.24.25. 26.27.28.smokers after acute myocardial infarction; the “smoker’s paradox” in a countrywide study. Eur Heart J 2001, 22:776-784. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T, et al: Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/11834444 Mortality Trial. Circulation 1993, 87:53-58. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief LH, Topol EJ: Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox” from 4-(Benzyloxy)-4-oxobutanoic acid the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995, 26:1222-1229. Bettencourt N, Mateus P, Dias C, Santos L, Adao L, Goncalves C, Simoes L, Gama V: The smoker’s hemodynamic reality? Rev Port Cardiol 2004, 23:547-555. Elosua R, Vega G, Rohlfs I, Aldasoro E, Navarro C, Cabades A, Demissie S, Segura A, Fiol M, Moreno-Iribas C, Echanove I, Tormo MJ, Arteagoitia JM, Sala J, Marrugat J, IBERICA investigators: Smoking and myocardial infarction case-fatality: hospital and population approach. Eur J Cardiovasc Prev Rehabil 2007, 14:561-567. Gaspar A, Nabalis S, Rocha S, Torres M, Pinto J, Azevedo P, Brandao A, Pereira MA, Correia A: Smoking in acute coronary syndromes he “smoker’s paradox” revisited. Rev Port Cardiol 2009, 28:425-437. Gottlieb S, Boyko V, Zahger D, Balkin J, Hod H, Pelled B, Stern S, Behar S: Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J Am Coll Cardiol 1996, 28:1506-1513. Gourlay SG, Rundle AC, Barron HV: Smoking and mortality following acute myocardial infarction: results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/8833965 2002, 4:101-107. Himbert D, Klutman M, Steg G, White K, Gulba DC: Cigarette smoking and a.